{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:41:50Z","timestamp":1793295710787,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Triptans are effective for many migraine patients, but some do not experience adequate efficacy and tolerability. The European Headache Federation (EHF) has proposed that patients with lack of efficacy and\/or tolerability of\u2009\u2265\u20092 triptans (\u2018triptan resistance\u2019) could be considered eligible for treatment with the novel medications from the ditan and gepant groups. There is little data on the frequency of \u2018triptan resistance\u2019.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We used patient self-report data from the German Migraine and Headache Society (DMKG) Headache Registry to assess triptan response and triptan efficacy and\/or tolerability failure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p> A total of 2284\u00a0adult migraine patients (females: 85.4%, age: 39.4\u2009\u00b1\u200912.8 years) were included. 42.5% (<jats:italic>n<\/jats:italic>\u2009=\u2009970) had failed\u2009\u2265\u20091 triptan, 13.1% (<jats:italic>n<\/jats:italic>\u2009=\u2009300) had failed\u2009\u2265\u20092 triptans (meeting the EHF definition of \u2018triptan resistance\u2019), and 3.9% (<jats:italic>n<\/jats:italic>\u2009=\u200988) had failed\u2009\u2265\u20093 triptans. Compared to triptan responders (current use, no failure, <jats:italic>n<\/jats:italic>\u2009=\u2009597), triptan non-responders had significantly more severe migraine (higher frequency (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), intensity (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05), and disability (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001)), that further increased with the level of triptan failure. Responders rates were highest for nasal and oral zolmitriptan, oral eletriptan and subcutaneous sumatriptan.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In the present setting (specialized headache care in Germany), 13.1% of the patients had failed\u2009\u2265\u20092 triptans. Triptan failure was associated with increased migraine severity and disability, emphasizing the importance of establishing an effective and tolerable acute migraine medication. Acute treatment optimization might include switching to one of the triptans with the highest responder rates and\/or to a different acute medication class.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The DMKG Headache Registry is registered with the German Clinical Trials Register (DRKS 00021081).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-023-01676-0","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T10:02:16Z","timestamp":1696932136000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry"],"prefix":"10.1186","volume":"24","author":[{"given":"Ruth","family":"Ruscheweyh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Gossrau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Dresler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Freilinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"F\u00f6rderreuther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charly","family":"Gaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Kraya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Neeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Ruschil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Straube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Scheidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim Patrick","family":"J\u00fcrgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"key":"1676_CR1","doi-asserted-by":"publisher","first-page":"4765","DOI":"10.1007\/s12325-020-01494-9","volume":"37","author":"E Leroux","year":"2020","unstructured":"Leroux E, Buchanan A, Lombard L et al (2020) Evaluation of patients with insufficient efficacy and\/or tolerability to triptans for the acute treatment of migraine: a systematic literature review. Adv Ther 37:4765\u20134796. https:\/\/doi.org\/10.1007\/s12325-020-01494-9","journal-title":"Adv Ther"},{"key":"1676_CR2","doi-asserted-by":"publisher","first-page":"333102422114377","DOI":"10.1177\/03331024221143773","volume":"43","author":"I de Boer","year":"2023","unstructured":"de Boer I, Verhagen IE, Souza MNP, Ashina M (2023) Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies. Cephalalgia 43:3331024221143773. https:\/\/doi.org\/10.1177\/03331024221143773","journal-title":"Cephalalgia"},{"key":"1676_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40120-021-00304-w","volume":"11","author":"A Gendolla","year":"2022","unstructured":"Gendolla A, Rauer N, Kraemer S et al (2022) Epidemiology, demographics, triptan contraindications, and prescription patterns of patients with migraine: a German claims database study. Neurol Ther 11:167\u2013183. https:\/\/doi.org\/10.1007\/s40120-021-00304-w","journal-title":"Neurol Ther"},{"key":"1676_CR4","doi-asserted-by":"publisher","first-page":"215013272096368","DOI":"10.1177\/2150132720963680","volume":"11","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Shewale AS, Lipton RB et al (2020) Migraine patients with cardiovascular disease and contraindications: an analysis of real-world claims data. J Prim Care Community Health 11:2150132720963680. https:\/\/doi.org\/10.1177\/2150132720963680","journal-title":"J Prim Care Community Health"},{"key":"1676_CR5","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/head.14304","volume":"62","author":"K Zebenholzer","year":"2022","unstructured":"Zebenholzer K, Gall W, Gleiss A et al (2022) Triptans and vascular comorbidity in persons over fifty: findings from a nationwide insurance database - a cohort study. Headache 62:604\u2013612. https:\/\/doi.org\/10.1111\/head.14304","journal-title":"Headache"},{"key":"1676_CR6","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/head.12404","volume":"54","author":"AJ Messali","year":"2014","unstructured":"Messali AJ, Yang M, Gillard P et al (2014) Treatment persistence and switching in triptan users: a systematic literature review. Headache 54:1120\u20131130. https:\/\/doi.org\/10.1111\/head.12404","journal-title":"Headache"},{"key":"1676_CR7","doi-asserted-by":"publisher","first-page":"107528","DOI":"10.1016\/j.pharmthera.2020.107528","volume":"211","author":"T de Vries","year":"2020","unstructured":"de Vries T, Villal\u00f3n CM, MaassenVanDenBrink A (2020) Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther 211:107528. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107528","journal-title":"Pharmacol Ther"},{"key":"1676_CR8","doi-asserted-by":"publisher","first-page":"333102422114168","DOI":"10.1177\/03331024221141686","volume":"43","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Blumenfeld A, Jensen CM et al (2023) Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: pooled results from three phase 3 randomized clinical trials. Cephalalgia 43:3331024221141686. https:\/\/doi.org\/10.1177\/03331024221141686","journal-title":"Cephalalgia"},{"key":"1676_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0333102419889350","volume":"40","author":"K Knievel","year":"2020","unstructured":"Knievel K, Buchanan AS, Lombard L et al (2020) Lasmiditan for the acute treatment of migraine: subgroup analyses by prior response to triptans. Cephalalgia 40:19\u201327. https:\/\/doi.org\/10.1177\/0333102419889350","journal-title":"Cephalalgia"},{"key":"1676_CR10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s10194-022-01502-z","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Lampl C, Amin FM et al (2022) European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain 23:133. https:\/\/doi.org\/10.1186\/s10194-022-01502-z","journal-title":"J Headache Pain"},{"key":"1676_CR11","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache Society (2021) The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice. Headache 61:1021\u20131039. https:\/\/doi.org\/10.1111\/head.14153","journal-title":"Headache"},{"key":"1676_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s10194-022-01447-3","volume":"23","author":"R Ruscheweyh","year":"2022","unstructured":"Ruscheweyh R, Klonowki T, Go\u00dfrau G et al (2022) The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients. J Headache Pain 23:74. https:\/\/doi.org\/10.1186\/s10194-022-01447-3","journal-title":"J Headache Pain"},{"key":"1676_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"key":"1676_CR14","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1212\/wnl.53.5.988","volume":"53","author":"WF Stewart","year":"1999","unstructured":"Stewart WF, Lipton RB, Whyte J et al (1999) An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 53:988\u2013994. https:\/\/doi.org\/10.1212\/wnl.53.5.988","journal-title":"Neurology"},{"key":"1676_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s10194-020-01110-9","volume":"21","author":"L Lombard","year":"2020","unstructured":"Lombard L, Farrar M, Ye W et al (2020) A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication. J Headache Pain 21:41. https:\/\/doi.org\/10.1186\/s10194-020-01110-9","journal-title":"J Headache Pain"},{"key":"1676_CR16","doi-asserted-by":"publisher","first-page":"333102423117485","DOI":"10.1177\/03331024231174855","volume":"43","author":"R Ruscheweyh","year":"2023","unstructured":"Ruscheweyh R, Dresler T, F\u00f6rderreuther S et al (2023) What do patients\u2019 efficacy and tolerability ratings of acute migraine medication tell us? Cross-sectional data from the DMKG Headache Registry. Cephalalgia 43:3331024231174855. https:\/\/doi.org\/10.1177\/03331024231174855","journal-title":"Cephalalgia"},{"key":"1676_CR17","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1212\/WNL.0000000000001256","volume":"84","author":"RB Lipton","year":"2015","unstructured":"Lipton RB, Fanning KM, Serrano D et al (2015) Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology 84:688\u2013695. https:\/\/doi.org\/10.1212\/WNL.0000000000001256","journal-title":"Neurology"},{"key":"1676_CR18","doi-asserted-by":"publisher","first-page":"11382","DOI":"10.1038\/s41598-020-68149-1","volume":"10","author":"OE Eren","year":"2020","unstructured":"Eren OE, Gaul C, Peikert A et al (2020) Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients. Sci Rep 10:11382. https:\/\/doi.org\/10.1038\/s41598-020-68149-1","journal-title":"Sci Rep"},{"key":"1676_CR19","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1046\/j.1468-2982.2002.00404.x","volume":"22","author":"MD Ferrari","year":"2002","unstructured":"Ferrari MD, Goadsby PJ, Roon KI, Lipton RB (2002) Triptans (serotonin, 5-HT1B\/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22:633\u2013658. https:\/\/doi.org\/10.1046\/j.1468-2982.2002.00404.x","journal-title":"Cephalalgia"},{"key":"1676_CR20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1177\/0333102413508661","volume":"34","author":"K Thorlund","year":"2014","unstructured":"Thorlund K, Mills EJ, Wu P et al (2014) Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis. Cephalalgia 34:258\u2013267. https:\/\/doi.org\/10.1177\/0333102413508661","journal-title":"Cephalalgia"},{"key":"1676_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1046\/j.1468-1331.1999.610043.x","volume":"6","author":"A Peikert","year":"1999","unstructured":"Peikert A, Becker WJ, Ashford EA et al (1999) Sumatriptan nasal spray: a dose-ranging study in the acute treatment of migraine. Eur J Neurol 6:43\u201349. https:\/\/doi.org\/10.1046\/j.1468-1331.1999.610043.x","journal-title":"Eur J Neurol"},{"key":"1676_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1726-4901(09)70300-4","volume":"70","author":"S-J Wang","year":"2007","unstructured":"Wang S-J, Fuh J-L, Wu Z-A (2007) Intranasal sumatriptan study with high placebo response in Taiwanese patients with migraine. J Chin Med Assoc 70:39\u201346. https:\/\/doi.org\/10.1016\/S1726-4901(09)70300-4","journal-title":"J Chin Med Assoc"},{"key":"1676_CR23","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1046\/j.1468-2982.2000.00082.x","volume":"20","author":"GM Davies","year":"2000","unstructured":"Davies GM, Santanello N, Lipton R (2000) Determinants of patient satisfaction with migraine therapy. Cephalalgia 20:554\u2013560. https:\/\/doi.org\/10.1046\/j.1468-2982.2000.00082.x","journal-title":"Cephalalgia"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01676-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01676-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01676-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T22:02:10Z","timestamp":1700604130000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01676-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1676"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01676-0","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]},"assertion":[{"value":"31 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study has been approved by the ethics committee of the Ludwig-Maximilians-University Munich (leading ethics committee, 20-004), and by the responsible ethics committee of every participating headache center. Informed consent was obtained from every subject before participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RR has received travel grants and\/or honoraria for lectures or advisory boards from Allergan\/AbbVie, Hormosan, Lilly, Lundbeck, Novartis and Teva.GG has received honoraria from Lilly, Novartis Pharma, Teva, Lundbeck, and research grants from Novartis Pharma during the last 3 years. She does not hold any stocks of pharmaceutical companies.TD has received honoraria for consulting and lectures from Hormosan Pharma, Novartis Pharma, and TEVA.TF received honoraria for advisory boards from Novartis, Teva and Lundbeck and honoraria for lectures from Novartis, Teva, Lilly, Bayer and UCS.SF received honoraria from Allergan\/AbbVie, Hormosan, Eli Lilly, Lundbeck, Novartis, Sanofi and Teva. She served on Advisory Boards for Hormosan, Eli Lilly, Lundbeck, Novartis, Sanofi and Teva.CG has received honoraria for consulting and lectures within the past 3 years from Abbvie, Lilly, Novartis Pharma, Hormosan Pharma, Gr\u00fcnenthal, Sanofi-Aventis, Lundbeck, Perfood, Reckitt and TEVA. His research is supported by a grant of the German Research Foundation (DFG). He does not hold any stocks of pharmaceutical companies. He is honorary secretary of the German Migraine and Headache Society.TK has received travel grants and\/or honoraria from Allergan\/AbbVie, Hormosan, Lilly, Novartis and Teva.LN received honoraria for lectures and advisory boards vrom Hormosan, Lilly, Novartis, Teva, AbbVie\/Allergan.VR received the Soyka award as a research grant from Novartis.AS has received honoraria for adboards and educational talks from Allergan\/AbbVie, Allergosan, Lilly, Lundbeck, Novartis, Sanofi, Teva.JS declares no conflict of interest.TPJ has received honoraria from Allergan\/AbbVie, Gr\u00fcnenthal, Hormosan, Lilly, Lundbeck, Novartis, Sanofi and Teva. He served on Advisory Boards and\/or consulted for Allergan\/AbbVie, Hormosan, Lilly, Lundbeck, Novartis and Teva.TPJ has received honoraria from Allergan\/AbbVie, Gr\u00fcnenthal, Hormosan, Lilly, Lundbeck, Novartis, Sanofi and Teva. He served on Advisory Boards and\/or consulted for Allergan\/AbbVie, Hormosan, Lilly, Lundbeck, Novartis and Teva.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}